We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos and GlaxoSmithKline Expand Anti-infectives Alliance

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Galapagos and GlaxoSmithKline Expand Anti-infectives Alliance "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

In December 2007, GSK and Galapagos initiated a program to discover and develop novel anti-infective drug candidates for GSK’s Infectious Diseases Centre of Excellence in Drug Discovery (ID CEDD). Galapagos is responsible for the discovery and development of natural product drug candidates through to clinical Proof of Concept, at which point GSK will have exclusive option to license each compound for further development and commercialization on a worldwide basis.
Under the terms of the alliance, Galapagos could be eligible to receive up to €95 million in upfront fees, development and regulatory milestones payments for each product candidate. If a product is commercialized, Galapagos may receive up to €120 million for achievement of specific sales milestones. Galapagos is also eligible to receive up to double-digit royalties on worldwide sales of alliance products.

“Following on the success and expansion of our osteoarthritis alliance, we are pleased that GSK has also expanded the anti-infectives alliance to include three additional targets,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “Together with the current programs advancing toward the clinic, we aim to progress these new anti-infective targets to deliver Phase IIa clinical candidates to GSK.”